Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Cortes JE, et al. Among authors: hochhaus a. Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22. Blood. 2018. PMID: 29567798 Free PMC article. Clinical Trial.
Interferon in chronic myeloid leukemia. A workshop report.
Griesshammer M, Hehlmann R, Hochhaus A, Talpaz M, Tura S, Stryckmans P, Allan NC, Tanzer J, Kolb HJ, Heimpel H. Griesshammer M, et al. Among authors: hochhaus a. Ann Hematol. 1993 Aug;67(2):101-6. doi: 10.1007/BF01788134. Ann Hematol. 1993. PMID: 8347729 Review.
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Löffler H, Pralle H, Queisser W, Tobler A. Hehlmann R, et al. Among authors: hochhaus a. Blood. 1999 Dec 1;94(11):3668-77. Blood. 1999. PMID: 10572078 Free article. Clinical Trial.
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Blood. 2000 Jan 1;95(1):62-6. Blood. 2000. PMID: 10607685 Free article. Clinical Trial.
679 results